The Filing Desk

ImmunityBio vs Century Therapeutics

ImmunityBio IBRX · Century Therapeutics IPSC · Biotechnology

ImmunityBio reported revenue of $113 million in fiscal 2025, about the same as Century Therapeutics' $109 million in fiscal 2025. ImmunityBio's revenue grew 668.3% in its latest year, and Century Therapeutics' grew 1556.8%. ImmunityBio had an operating margin of -226.0%, against -15.8% at Century Therapeutics. Free cash flow was −$309 million at ImmunityBio and −$105 million at Century Therapeutics.

Side by side

ImmunityBioCentury Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$113M$109M
Revenue growth668.3%1,556.8%
Revenue growth a year, last 5 years185.2%—
Gross margin99.3%—
Operating margin−226.0%−15.8%
Net margin−310.2%−8.8%
Free cash flow−$309M−$105M
Free cash flow margin−272.6%−95.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count31.3%10.1%
Last close$6.57$1.32
P/E at the last close——
Insider trades, last 12 monthssold $8.4 millionbought $79,511, sold $71,284
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ImmunityBioCentury Therapeutics
Operating margin
Percent of revenue
ImmunityBioCentury Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmunityBioCentury Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ImmunityBio and Century Therapeutics pages.